Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Código QR

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Nadine Abdallah,1 Misako Nagasaka,2,3 Eman Abdulfatah,4 Dongping Shi,4 Antoinette J Wozniak,2 Ammar Sukari2 1Department of Internal Medicine, Wayne State University, Detroit, MI 48201, USA; 2Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, De...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Checkpoint inhibitor transformation of pathology second primary Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5ec7a9bbf8d14c17a509a9cc8032296a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
por: Nagasaka M, et al.
Publicado: (2019)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Chengming Liu, et al.
Publicado: (2021)

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors  in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021)

Oligoprogression in Non-Small Cell Lung Cancer
por: Daijiro Harada, et al.
Publicado: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer
por: Liliang Xia, et al.
Publicado: (2021)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
por: Aya Yamashita, et al.
Publicado: (2021)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
por: KE Ping, et al.
Publicado: (2021)

Clinical case of long-term use of durvalumab in the treatment of advanced small-cell lung cancer
por: Galina B. Statsenko, et al.
Publicado: (2020)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)

Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Ewa Surmiak, et al.
Publicado: (2021)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Kimberly M. Burcher, et al.
Publicado: (2021)

Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models
por: Woorim Kim, et al.
Publicado: (2021)

Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
por: María Rodríguez Plá, et al.
Publicado: (2021)

Small cell lung cancer transformation during antitumor therapies: A systematic review
por: Chai Xing, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor
por: Tory Starzyk, MA, et al.
Publicado: (2022)

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
por: Shijie Shang, et al.
Publicado: (2021)

Polymyalgia rheumatica with normal inflammatory indices at the time of diagnosis: can we just move a step forward?
por: Ciro Manzo, et al.
Publicado: (2020)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
por: Wiktoria Blaszczak, et al.
Publicado: (2021)

Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review
por: Hadi SHSM, et al.
Publicado: (2021)

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
por: Rizzo M, et al.
Publicado: (2021)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Yahua Wu, et al.
Publicado: (2022)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Takuma Imakita, et al.
Publicado: (2021)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Thomas Bartl, et al.
Publicado: (2021)

Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts
por: Yoshihide Suzuki, et al.
Publicado: (2021)

Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
por: Albina S. Zhabina, et al.
Publicado: (2021)

Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor
por: Vicky Mai, et al.
Publicado: (2021)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
por: Nikolai A. Ognerubov, et al.
Publicado: (2021)

Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
por: Can Öztürk, et al.
Publicado: (2021)

Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
por: Tan Y, et al.
Publicado: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Shinsuke Suzuki, et al.
Publicado: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
por: Jiamin Sheng, et al.
Publicado: (2021)

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
por: Marc-Oliver Grimm, et al.
Publicado: (2021)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yi-Dan Yan, et al.
Publicado: (2021)

Systemic Therapy for Microsatellite Instability Small Bowel Adenocarcinoma With Mesenteric Vascular Embolism as Initial Symptom: A Case Report
por: Zhongyi Dong, et al.
Publicado: (2021)